305 related articles for article (PubMed ID: 15589576)
21. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
[TBL] [Abstract][Full Text] [Related]
22. Monitoring of endometrial K-ras mutation in tamoxifen-treated patients with breast cancer.
Tsujioka H; Hachisuga T; Fukuoka M; Ueda T; Miyahara D; Horiuchi S; Shirota K; Yoshizato T; Emoto M; Miyamoto S; Kawarabayashi T
Int J Gynecol Cancer; 2009 Aug; 19(6):1052-6. PubMed ID: 19820367
[TBL] [Abstract][Full Text] [Related]
23. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
[TBL] [Abstract][Full Text] [Related]
24. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression.
Salvesen HB; Stefansson I; Kretzschmar EI; Gruber P; MacDonald ND; Ryan A; Jacobs IJ; Akslen LA; Das S
Int J Oncol; 2004 Dec; 25(6):1615-23. PubMed ID: 15547698
[TBL] [Abstract][Full Text] [Related]
25. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
26. Molecular pathology of endometrial carcinoma.
Matias-Guiu X; Prat J
Histopathology; 2013 Jan; 62(1):111-23. PubMed ID: 23240673
[TBL] [Abstract][Full Text] [Related]
27. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.
Lax SF; Kendall B; Tashiro H; Slebos RJ; Hedrick L
Cancer; 2000 Feb; 88(4):814-24. PubMed ID: 10679651
[TBL] [Abstract][Full Text] [Related]
28. Uterine malignancy following tamoxifen use in breast cancer patients in Iran: case series and literature review.
Behtash N; Hashemi R; Karimi Zarchi M
Asian Pac J Cancer Prev; 2009; 10(1):163-6. PubMed ID: 19469647
[TBL] [Abstract][Full Text] [Related]
29. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
[TBL] [Abstract][Full Text] [Related]
30. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases.
Bussaglia E; del Rio E; Matias-Guiu X; Prat J
Hum Pathol; 2000 Mar; 31(3):312-7. PubMed ID: 10746673
[TBL] [Abstract][Full Text] [Related]
31. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma.
Caduff RF; Johnston CM; Svoboda-Newman SM; Poy EL; Merajver SD; Frank TS
Am J Pathol; 1996 May; 148(5):1671-8. PubMed ID: 8623934
[TBL] [Abstract][Full Text] [Related]
32. Novel molecular profiles of endometrial cancer-new light through old windows.
Doll A; Abal M; Rigau M; Monge M; Gonzalez M; Demajo S; Colás E; Llauradó M; Alazzouzi H; Planagumá J; Lohmann MA; Garcia J; Castellvi S; Ramon y Cajal J; Gil-Moreno A; Xercavins J; Alameda F; Reventós J
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):221-9. PubMed ID: 18061438
[TBL] [Abstract][Full Text] [Related]
33. Endometrial carcinoma in tamoxifen-treated breast cancer patient: clinicopathological, immunohistochemical, and genetic analysis.
Esteller M; Garcia A; Martinez-Palones JM; Xercavins J; Reventos J
Int J Gynecol Pathol; 1999 Oct; 18(4):387-91. PubMed ID: 10542949
[TBL] [Abstract][Full Text] [Related]
34. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.
Lax SF
Virchows Arch; 2004 Mar; 444(3):213-23. PubMed ID: 14747944
[TBL] [Abstract][Full Text] [Related]
35. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers.
Maxwell GL; Risinger JI; Hayes KA; Alvarez AA; Dodge RK; Barrett JC; Berchuck A
Clin Cancer Res; 2000 Aug; 6(8):2999-3005. PubMed ID: 10955777
[TBL] [Abstract][Full Text] [Related]
36. [Genetic abnormalities in endometrial cancer].
Takeshima N; Hirai Y
Nihon Rinsho; 2004 Oct; 62 Suppl 10():254-8. PubMed ID: 15535246
[No Abstract] [Full Text] [Related]
37. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
[TBL] [Abstract][Full Text] [Related]
38. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics.
Risinger JI; Hayes K; Maxwell GL; Carney ME; Dodge RK; Barrett JC; Berchuck A
Clin Cancer Res; 1998 Dec; 4(12):3005-10. PubMed ID: 9865913
[TBL] [Abstract][Full Text] [Related]
39. Beta- and gamma-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability.
Palacios J; Catasús L; Moreno-Bueno G; Matias-Guiu X; Prat J; Gamallo C
Virchows Arch; 2001 May; 438(5):464-9. PubMed ID: 11407474
[TBL] [Abstract][Full Text] [Related]
40. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma.
Katase K; Sugiyama Y; Hasumi K; Yoshimoto M; Kasumi F
Cancer; 1998 May; 82(9):1698-703. PubMed ID: 9576291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
